标题: PegIFN results in higher serological, but not virological, response rates [打印本页] 作者: 肝胆速递 时间: 2012-9-1 15:19 标题: PegIFN results in higher serological, but not virological, response rates
本帖最后由 肝胆速递 于 2012-9-1 15:20 编辑
Antivir Ther. 2012 Aug 16. doi: 10.3851/IMP2319. [Epub ahead of print]
peginterferon results in higher serological, but not virological, response rates when compared to continuous entecavir.[No authors listed]
Abstract
Background.
HBeAg and HBsAg clearance are associated with an improved prognosis in chronic hepatitis B patients (CHB). These endpoints are more often achieved with a one year course of peginterferon (PEG-IFN) compared with one year of nucleos(t)ide analogue (NA) therapy. However, prolonged NA therapy may result in comparable serological response rates as with PEG-IFN.Methods. We compared serological and virological response rates among HBeAg-positive CHB patients treated with long-term continuous entecavir (ETV) (n=91) for a median of 92 (IQR 50-132) weeks or one year of PEG-IFN (n=266) with comparable follow up.Results. Median follow-up was 92 weeks (IQR 78-198) for patients treated with PEG-IFN, and 92 (IQR 50-132) weeks for patients treated with ETV. Finite PEG-IFN therapy resulted in significantly higher rates of HBeAg seroconversion (adjusted hazard ratio (HR): 3.16,p<0.001) and HBsAg clearance (HR 5.66,p=0.027) when compared to prolonged ETV treatment, whereas ETV resulted in higher rates of HBV DNA undetectability (OR 31.14,p<0.001) also after adjustment for HBV genotype and other relevant baseline factors.
Conclusions. Our study shows that finite PEG-IFN is associated with a higher probability of serological, but not virological, response for HBeAg-positive CHB patients when compared to prolonged ETV, even after correction for baseline differences.